Which companies overlap with Russian Cardiology Research and Production Center's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/russian-cardiology-research-and-production-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Russian Cardiology Research and Production Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Russian Cardiology Research and Production Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
atorvastatin, aspirin, losartan, amlodipine	atorvastatin, aspirin, losartan, amlodipine	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker	Multiple: HMG-CoA reductase, cyclooxygenase, AT1 receptor, L-type calcium channel	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Russian Cardiology Research and Production Center:

Cite this brief

Drug Landscape (2026). Russian Cardiology Research and Production Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/russian-cardiology-research-and-production-center. Accessed 2026-05-18.